Inga P.
- Country
- Germany
- Department
- Institut für Klinisch-Onkologische Forschung (IKF)
Research Overview
- Phase 3 Study of Vepugratinib and Combination Therapy in Adults with Untreated FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Saruparib (AZD5305) with New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
- Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Data & Insights
Has run more than one trial at 76 of 235 partner sites.
Specializations
Prostate Cancer Treatment
This investigator specializes in treating metastatic castration-sensitive prostate cancer (mCSPC), with particular focus on developing innovative therapeutic approaches.
- Novel Hormonal Agent Combinations
- Advanced Treatment Protocols
- Metastatic Disease Management
The research involves evaluating various therapeutic combinations to improve treatment outcomes for prostate cancer patients.
Chemotherapy Optimization
Focused on optimizing docetaxel-based treatment regimens in combination with hormonal therapy for metastatic hormone-sensitive prostate cancer.
- Dosing Schedule Evaluation
- Safety Profile Assessment
- Combination Therapy Approaches
The investigator explores treatment schedules to enhance therapeutic efficacy while managing adverse events.
Urothelial Cancer Research
Investigating advanced treatments for locally advanced and metastatic urothelial cancer, including novel therapeutic combinations.
- Immunotherapy Integration
- Targeted Treatment Approaches
- Progressive Disease Management
The focus includes evaluating combination therapies and monotherapy options for urothelial cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.